LifeProNow

MAY 8, 2023

The standard therapy for these patients consists of intensive salvage immunochemotherapy followed by high-dose chemotherapy and HSCT for those whose disease responds to the salvage therapy and are eligible for transplant. Any-grade neurologic events were reported in 10.9% Median PFS was not reached (95% CI: 12.6-NR) months (95% CI: 4.3-8.6)

Chemotherapy 130

Chemotherapy Adverse Reactions 130

pharmaphorum

APRIL 1, 2021

The FDA has approved Sanofi’s Sarclisa (isatuximab) in combination with a new chemotherapy regimen for advanced multiple myeloma, building on a first approval last year. In the trial, 8% of patients dropped out because of adverse events and 2.8% quit because of an infection.

Adverse Reactions 52

Adverse Reactions Labelling Chemotherapy 52

LifeProNow

APRIL 30, 2023

The most common adverse events in those treated with XTANDI plus leuprolide were fatigue, hot flush, and arthralgia and in those treated with XTANDI monotherapy were fatigue, gynecomastia, and arthralgia. Grade 3-4 ischemic events occurred in 1.4% events led to death in 0.4% of patients on XTANDI versus 0.7% on placebo.

Adverse Reactions 130

Adverse Reactions Chemotherapy Diabetes 130

pharmaphorum

JANUARY 26, 2022

The regulatory move applies only to trials of magrolimab given alongside Bristol-Myers Squibb’s Vidaza (azacitidine), and stems from an “imbalance” in investigator-reported serious adverse events between study arms, said the drugmaker.

Adverse Reactions 40

Adverse Reactions Chemotherapy Immunity Immunization 40

European Pharmaceutical Review

NOVEMBER 24, 2022

s Libtayo ® (cemiplimab) for adults with recurrent or metastatic cervical cancer and disease progression while on or after platinum-based chemotherapy. “Libtayo ® was the first programmed cell death protein (PD)-1 inhibitor to demonstrate significant improvements in survival compared to chemotherapy in a Phase III trial.

Chemotherapy 86

Chemotherapy Immunity Immunization Adverse Reactions 86

The Thyroid Pharmacist

SEPTEMBER 1, 2023

They include anesthetics, antacids, anti-anxiety medications, antibiotics, antidepressants, antifungals, cholesterol-lowering medications, anti-malarial medications, chemotherapy, appetite suppressants, arthritis medications, psychotropics, and steroids. Who is Likely to Have an Adverse Reaction to Fluoride, and What are the Symptoms?

Adverse Reactions 116

Adverse Reactions Compounding Chemotherapy Labelling 116

LifeProNow

APRIL 19, 2023

Monitor for neurologic events after treatment with ABECMA. Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS) including fatal and life-threatening reactions, occurred in patients following treatment with ABECMA. Provide supportive care and/or corticosteroids as needed. Three cases of Grade 2 HLH/MAS resolved.

Adverse Reactions 100

Adverse Reactions Vaccines Immunity Immunization 100